Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes

(2021) Neil Tanday et al.   Frontiers in Endocrinology

Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents

(2020) Jing Han et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Behavioural and neurochemical mechanisms underpinning the feeding-suppressive effect of GLP-1/CCK combinatorial therapy

(2020) Emma Roth et al.   Molecular Metabolism

Structure-Activity Relationships and Characterization of Highly Selective, Long Acting, Peptide-based Cholecystokinin 1 Receptor (CCK-1R) Agonists

(2019) Ulrich Sensfuss et al.   JOURNAL OF MEDICINAL CHEMISTRY

The chronic administration of two novel long-acting Xenopus glucagon-like peptide-1 analogs xGLP159 and xGLP296 potently improved systemic metabolism and glycemic control in rodent models

(2019) Jing Han et al.   FASEB JOURNAL

Long-acting CCK analogue NN9056 lowers food intake and body weight in obese Göttingen Minipigs

(2019) Berit Ø. Christoffersen et al.   INTERNATIONAL JOURNAL OF OBESITY

Glucagon-like peptide 1 (GLP-1)

(2019) T.D. Müller et al.   Molecular Metabolism

Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors

(2019) Rie Suzuki et al.   JOURNAL OF MEDICINAL CHEMISTRY

A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice

(2018) David C. Hornigold et al.   APPETITE

Preparation and Pharmaceutical Characterizations of Lipidated Dimeric Xenopus Glucagon-Like Peptide-1 Conjugates

(2018) Jing Han et al.   BIOCONJUGATE CHEMISTRY

Xenopus -derived glucagon-like peptide-1 and polyethylene-glycosylated glucagon-like peptide-1 receptor agonists: long-acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities

(2018) Jing Han et al.   BRITISH JOURNAL OF PHARMACOLOGY

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

(2018) Daniel J. Drucker   Cell Metabolism

Lipidation and conformational constraining for prolonging the effects of peptides: Xenopus glucagon-like peptide 1 analogues with potent and long-acting hypoglycemic activity

(2018) Jing Han et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs

(2018) Jing Han et al.   MOLECULAR PHARMACEUTICS

Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes

(2018) Varun Pathak et al.   PEPTIDES

Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents

(2018) Jing Han et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases

(2018) Christoffer Clemmensen et al.   Nature Reviews Endocrinology

Design, synthesis and biological evaluation of PEGylated Xenopus glucagon-like peptide-1 derivatives as long-acting hypoglycemic agents

(2017) Jing Han et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues

(2017) Esben M. Bech et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists

(2017) Andreas Evers et al.   JOURNAL OF MEDICINAL CHEMISTRY

Late-stage lipidation of fully elaborated tryptophan-containing peptides for improved pharmacokinetics

(2017) Chunhui Huang et al.   TETRAHEDRON LETTERS

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

(2016) Matthias H. Tschöp et al.   Cell Metabolism

Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery

(2016) Peng-Yu Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat–Fed Mice

(2015) Nigel Irwin et al.   DIABETES

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

(2015) Jesper Lau et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents

(2014) J. L. Trevaskis et al.   DIABETES OBESITY & METABOLISM

Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications

(2014) Bikash Manandhar et al.   JOURNAL OF MEDICINAL CHEMISTRY

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

(2014) Brian Finan et al.   NATURE MEDICINE

Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice

(2013) N. Irwin et al.   DIABETES OBESITY & METABOLISM

Species- and Dose-Specific Pancreatic Responses and Progression in Single- and Repeat-Dose Studies with GI181771X

(2013) James R. Myer et al.   TOXICOLOGIC PATHOLOGY

The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice

(2012) K. Fosgerau et al.   DIABETES OBESITY & METABOLISM

Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes

(2012) N. Irwin et al.   DIABETOLOGIA

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

(2012) Juris J. Meier   Nature Reviews Endocrinology

Potential of the gastric motility drug lorglumide in prostate cancer imaging

(2011) Alexander Sturzu et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

A Novel Human-Based Receptor Antagonist of Sustained Action Reveals Body Weight Control by Endogenous GLP-1

(2010) James T. Patterson et al.   ACS Chemical Biology

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

(2009) Jonathan W Day et al.   Nature Chemical Biology